JNJ's Double-Digit Growth Target Has Substance Behind the Promise

Stelara's biosimilar erosion represents the single largest revenue replacement challenge in JNJ's modern history. At peak revenue, Stelara contributed roughly 22% of total pharmaceutical sales. Biosimilar competition typically erodes 60-80% of branded revenue within three years of entry, based on historical patterns from other large biologic patent expirations. Humira's trajectory at AbbVie provides the closest analogue: Humira biosimilars launched in 2023, and AbbVie has managed the transition through pipeline execution and M&A.

JNJ's replacement strategy rests on three pillars. First, the Darzalex franchise in oncology, which generated over $10 billion in fiscal 2025 revenue and continues to grow at double-digit rates as it expands into earlier lines of therapy. Second, the immunology pipeline beyond Stelara, including tremfya (guselkumab) which received expanded indications. Third, the medtech segment, which grew 5.2% organically in fiscal 2025 and benefits from an ageing global population requiring more surgical procedures.

The Kenvue consumer health spinoff in 2023 simplified the story. JNJ is now a pure pharmaceutical and medtech company, which improves the quality of the earnings stream and justifies a higher multiple. Pre-spinoff, the consumer business dragged on margins and growth. Post-spinoff, the remaining entity generates operating margins above 26.7% with a clear path to further expansion.

JNJ generated $19.7 billion in free cash flow in fiscal 2025. That figure has been remarkably stable, ranging between $17.2 billion and $19.8 billion over the past five years despite significant portfolio changes, pandemic disruptions, and the Kenvue separation. Consistency at this scale is rare.

The dividend currently yields 2.17%, modest by historical JNJ standards but well covered by earnings. The payout ratio sits near 45% of earnings, leaving substantial room for dividend growth, share repurchases, and bolt-on acquisitions. Management repurchased approximately $6 billion in shares during fiscal 2025 at an average price roughly 15% below the current level. That is capital allocation competence.

The balance sheet carries more debt than ideal, a legacy of the Kenvue transaction and prior acquisitions, but interest coverage remains comfortable at over 10x. Credit ratings of AAA from S&P (one of only two US corporates with that rating) provide access to the cheapest possible debt financing for future M&A. JNJ's cost of capital is a structural competitive advantage that most investors underappreciate.

Compare JNJ's capital return profile to peers: Pfizer slashed its dividend expectations post-COVID. Merck's free cash flow is lumpy due to Keytruda's patent trajectory. AbbVie loaded up on debt to fund Allergan. JNJ is the cleanest capital allocation story in large-cap pharma.

At 21.8x trailing earnings and 20.8x forward estimates, JNJ trades at a discount to the S&P 500 healthcare sector average of approximately 24x forward earnings. For a company with AAA credit, a 64-year dividend growth streak, 72.8% gross margins, and a credible path to double-digit earnings growth, that discount is hard to justify.

The stock has rallied from a 52-week low of $142 to near its high of $251.71, a 77% move that reflects the market's belated recognition that the Kenvue-simplified JNJ is a higher-quality asset. The beta of 0.33 makes JNJ one of the lowest-volatility large-caps in the market, which matters in a macro environment where recession fears periodically spike. The 50-day moving average at $241 and 200-day at $202 both slope upward, confirming the technical trend aligns with the fundamental improvement.

The analyst consensus target of $249.75 offers limited upside from current levels, but JNJ's total return profile includes the 2.17% dividend yield plus mid-single-digit earnings growth at minimum. In a portfolio context, JNJ serves as a compounder that delivers 8-10% annual total returns with a third of the market's volatility.

The talc litigation, which has weighed on JNJ's multiple for years, is approaching resolution. JNJ's proposed $6.5 billion settlement plan, channelled through a subsidiary bankruptcy filing, gained significant creditor support in recent proceedings. While final resolution remains subject to court approval, the probability-weighted litigation liability has decreased meaningfully over the past twelve months.

Removal of the talc discount alone could add 1-2 multiple points to JNJ's forward P/E, translating to approximately $20-40 per share in value. The market has partially priced this in during the recent rally, but the full resolution catalyst remains ahead. Once the uncertainty is removed entirely, JNJ should trade at or above the sector average multiple, given its superior capital allocation track record and balance sheet quality.